Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meindert Danhof

Showing results (31-40 of 230) with videos related to

Pageof 23
Sort By:
Pharmaceutical Research|October 5, 2007
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in ratsAshraf Yassen, Erik Olofsen, Jingmin Kan, et al.
Drug Metabolism and Pharmacokinetics|March 3, 2009
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelingBart A Ploeger, Piet H van der Graaf, Meindert Danhof
Pharmaceutical Research|July 20, 2005
Disease system analysis: basic disease progression models in degenerative diseaseTeun M Post, Jan I Freijer, Joost DeJongh, et al.
Journal of Clinical Pharmacology|March 29, 2014
Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young agesAshley Strougo, Ashraf Yassen, Claire Monnereau, et al.
Drug Discovery Today|September 15, 2018
The future of drug development: the paradigm shift towards systems therapeuticsMeindert Danhof, Kevin Klein, Pieter Stolk, et al.
International Journal of Pharmaceutics|October 16, 2003
Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studiesGai Ling Li, Arne Grossklaus, Meindert Danhof, et al.
Journal of Clinical Pharmacology|September 3, 2015
Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitorAmit Taneja, Sean P Oosterholt, Meindert Danhof, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 14, 2011
A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditionsAshley Strougo, Ashraf Yassen, Walter Krauwinkel, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 2, 2010
Advances in paediatric pharmacokineticsCatherijne A J Knibbe, Elke H J Krekels, Meindert Danhof
Clinical Pharmacokinetics|May 1, 2007
Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphineAshraf Yassen, Erik Olofsen, Jingmin Kan, et al.
Pageof 23

Showing results (31-40 of 230) with videos related to

Sort By:
Pageof 23
Pharmaceutical Research|October 5, 2007
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in ratsAshraf Yassen, Erik Olofsen, Jingmin Kan, et al.
Drug Metabolism and Pharmacokinetics|March 3, 2009
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelingBart A Ploeger, Piet H van der Graaf, Meindert Danhof
Pharmaceutical Research|July 20, 2005
Disease system analysis: basic disease progression models in degenerative diseaseTeun M Post, Jan I Freijer, Joost DeJongh, et al.
Journal of Clinical Pharmacology|March 29, 2014
Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young agesAshley Strougo, Ashraf Yassen, Claire Monnereau, et al.
Drug Discovery Today|September 15, 2018
The future of drug development: the paradigm shift towards systems therapeuticsMeindert Danhof, Kevin Klein, Pieter Stolk, et al.
International Journal of Pharmaceutics|October 16, 2003
Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studiesGai Ling Li, Arne Grossklaus, Meindert Danhof, et al.
Journal of Clinical Pharmacology|September 3, 2015
Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitorAmit Taneja, Sean P Oosterholt, Meindert Danhof, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 14, 2011
A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditionsAshley Strougo, Ashraf Yassen, Walter Krauwinkel, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 2, 2010
Advances in paediatric pharmacokineticsCatherijne A J Knibbe, Elke H J Krekels, Meindert Danhof
Clinical Pharmacokinetics|May 1, 2007
Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphineAshraf Yassen, Erik Olofsen, Jingmin Kan, et al.
Pageof 23